system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, OBJECTIVE, METHODS, RESULTS. Meshes: Adult, Body Mass Index, Calcium-Binding Proteins, Cross-Sectional Studies, DNA-Binding Proteins, Female, Hospitals, University, Humans, Insulin Resistance, Nerve Tissue Proteins, Outpatient Clinics, Hospital, Ovary, Overweight, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, Prospective Studies, Reproducibility of Results, Turkey, Ultrasonography, Prenatal, Up-Regulation, Young Adult.
user
Are plasma nesfatin-1 levels increased in patients with polycystic ovary syndrome? Context: Nesfatin-1 is a recently discovered neuropeptide derived from its precursor nucleobindin-2 (NUCB2) and has been implicated in the regulation of feeding and energy metabolism. It is located in the brain and also produced at the periphery and present in the plasma. However, its pathophysiological role in humans remains unknown. Polycystic ovary syndrome (PCOS) is commonly presented with obesity, insulin resistance, hyperandrogenemia and hirsutism. To characterize serum nesfatin-1 levels in PCOS women and determine association of nesfatin-1 with metabolic parameters. It is a cross-sectional study of 55 PCOS and 28 healthy women matched in age, in a university hospital setting. Anthropometric, hormonal, metabolic parameters and nesfatin-1 blood levels were determined. Nesfatin-1 levels were significantly higher in PCOS group compared with the controls 371.43 ± 2.50 versus 275.55 ± 1.74 pg/mL. Multivariate logistic regression analysis that contains: nesfatin-1, body mass index and homeostasis model assessment index revealed significant correlation of nesfatin-1 with the existence of PCOS (p < 0.05).
assistant
Higher nesfatin-1 levels in PCOS women compared to control group may suggest a possibility that nesfatin-1 may play some role in the PCOS. Final Decision: yes